163 related articles for article (PubMed ID: 14688254)
1. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing.
Zhang M; Coffino P
J Biol Chem; 2004 Mar; 279(10):8635-41. PubMed ID: 14688254
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal.
Dantuma NP; Heessen S; Lindsten K; Jellne M; Masucci MG
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8381-5. PubMed ID: 10890896
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
[TBL] [Abstract][Full Text] [Related]
4. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
Yin Y; Manoury B; Fåhraeus R
Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
[TBL] [Abstract][Full Text] [Related]
5. Avoiding proteasomal processing: the case of EBNA1.
Dantuma NP; Sharipo A; Masucci MG
Curr Top Microbiol Immunol; 2002; 269():23-36. PubMed ID: 12224511
[TBL] [Abstract][Full Text] [Related]
6. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
[TBL] [Abstract][Full Text] [Related]
7. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition.
Sharipo A; Imreh M; Leonchiks A; Brändén C; Masucci MG
FEBS Lett; 2001 Jun; 499(1-2):137-42. PubMed ID: 11418128
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ubiquitin-dependent proteolysis by a synthetic glycine-alanine repeat peptide that mimics an inhibitory viral sequence.
Leonchiks A; Stavropoulou V; Sharipo A; Masucci MG
FEBS Lett; 2002 Jul; 522(1-3):93-8. PubMed ID: 12095625
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ubiquitin/proteasome-dependent proteolysis in Saccharomyces cerevisiae by a Gly-Ala repeat.
Heessen S; Dantuma NP; Tessarz P; Jellne M; Masucci MG
FEBS Lett; 2003 Dec; 555(2):397-404. PubMed ID: 14644450
[TBL] [Abstract][Full Text] [Related]
10. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus.
Lautscham G; Rickinson A; Blake N
Microbes Infect; 2003 Apr; 5(4):291-9. PubMed ID: 12706442
[TBL] [Abstract][Full Text] [Related]
11. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
12. Immunology. Hide and seek in the peptidome.
Yewdell JW
Science; 2003 Sep; 301(5638):1334-5. PubMed ID: 12958347
[No Abstract] [Full Text] [Related]
13. Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5.
Pokrovskaja K; Mattsson K; Kashuba E; Klein G; Szekely L
J Gen Virol; 2001 Feb; 82(Pt 2):345-358. PubMed ID: 11161273
[TBL] [Abstract][Full Text] [Related]
14. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
Voisset C; Daskalogianni C; Contesse MA; Mazars A; Arbach H; Le Cann M; Soubigou F; Apcher S; Fåhraeus R; Blondel M
Dis Model Mech; 2014 Apr; 7(4):435-44. PubMed ID: 24558096
[TBL] [Abstract][Full Text] [Related]
15. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.
Tellam J; Sherritt M; Thomson S; Tellam R; Moss DJ; Burrows SR; Wiertz E; Khanna R
J Biol Chem; 2001 Sep; 276(36):33353-60. PubMed ID: 11435434
[TBL] [Abstract][Full Text] [Related]
16. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
17. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing.
Kwun HJ; da Silva SR; Shah IM; Blake N; Moore PS; Chang Y
J Virol; 2007 Aug; 81(15):8225-35. PubMed ID: 17522213
[TBL] [Abstract][Full Text] [Related]
18. Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate.
Zhang M; Pickart CM; Coffino P
EMBO J; 2003 Apr; 22(7):1488-96. PubMed ID: 12660156
[TBL] [Abstract][Full Text] [Related]
19. The 20S proteasome mediates the degradation of mouse and yeast ornithine decarboxylase in yeast cells.
Mamroud-Kidron E; Rosenberg-Hasson Y; Rom E; Kahana C
FEBS Lett; 1994 Jan; 337(3):239-42. PubMed ID: 8293806
[TBL] [Abstract][Full Text] [Related]
20. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.
Apcher S; Daskalogianni C; Manoury B; Fåhraeus R
PLoS Pathog; 2010 Oct; 6(10):e1001151. PubMed ID: 20976201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
